Bluejay Diagnostics, Inc. (BJDX)
| Market Cap | 1.85M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -8.59M |
| Shares Out | 537.68K |
| EPS (ttm) | -163.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 17,582 |
| Open | 3.549 |
| Previous Close | 3.530 |
| Day's Range | 3.350 - 3.650 |
| 52-Week Range | 3.030 - 386.800 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Mar 27, 2025 |
About BJDX
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers Symphony platform, a technology platform comprising Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. It also provides ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the company develops Symphony IL-6 test for the monitoring of disease progr... [Read more]
Financial Performance
Financial StatementsNews
Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
ACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients
Results from primary analysis of the SYMON-I pilot clinical study consistent with IL-6 as a predictor of patients who have a mortality event with 28 days after sepsis and septic shock diagnosis and ar...
Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering
ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering
ACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)
This Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives.
Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results
ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests...
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
ACTON, Mass., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results
ACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy
ACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platfor...
Bluejay Diagnostics Reports First Quarter 2023 Financial Results
ACTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Symp...
Bluejay Diagnostics Reports 2022 Financial Results
ACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing rapid tests using whole blood on its Sy...
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
ACTON, Mass. and WEST WARWICK, R.I., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed ...
Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results
ACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a clinical-stage medical diagnostics company developing rapid, near-patient tests...
Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 400 points on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-pat...
Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure
Webinar to be held Thursday, August 25th @ 11:00am EDT Webinar to be held Thursday, August 25th @ 11:00am EDT
Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022
Demonstrated 98% NPV 1 to Identify COVID-19 Patients at Risk for Severe Illness
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
ACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-p...
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
ACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-pat...
Why Bluejay Diagnostics Shares Are Surging Higher Today
Shares of small-cap penny stock Bluejay Diagnostics, Inc. (NASDAQ: BJDX) are trading higher after the company announced that the FDA has agreed to consider its plan to pursue a De Novo submission for ...
Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results
ACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, ra...
Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance
ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective,...
Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer
ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a late-stage, pre-revenue diagnostics company focused on developing cost-effective...
Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Testing program underway for lead product candidate, the Symphony IL-6 Test, in support of an FDA Marketing Application, planned for Q3 2022